Hospital
Monadnock Community Hospital
Monadnock Community Hospital was paid $8.59M by Medicaid between Jan 2018 and Nov 2024, across 126 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoMONADNOCK COMMUNITY HOSPITAL
PETERBOROUGH, NH 03458
PETERBOROUGH, NH 03458
33aNPI1457304149assigned 05/17/2006
33bProvider typeCritical Access Hospital
28Total paid$8.59M
24GClaims177,930
24DCodes billed126
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in New Hampshire
Rank by total paid#1 of 9
Median peer was paid$5.24M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,960 | $1.01M | |
| 2019 | 31,962 | $1.08M | |
| 2020 | 30,383 | $1.35M | |
| 2021 | 40,511 | $2.15M | |
| 2022 | 29,945 | $1.85M | |
| 2023 | 7,932 | $717K | |
| 2024incomplete | 5,237 | $438K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 12,464 | 7,627 | $1.93M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 10,878 | 6,753 | $1.80M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 4,511 | 2,675 | $1.17M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.5% | 527 | 400 | $644K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.7% | 6,692 | 1,890 | $400K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 4,795 | 3,031 | $328K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 840 | 554 | $297K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.6% | 4,105 | 1,247 | $223K |
| 71045 | Radiologic examination, chest; single view | 2.0% | 2,288 | 1,573 | $171K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 1,999 | 1,603 | $139K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 1,950 | 1,095 | $130K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 3,220 | 2,158 | $112K |
114 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 800 | $109K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 1,596 | $94K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,943 | $78K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,314 | $68K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,446 | $63K |
| 80053 | Comprehensive metabolic panel | <1% | 10,178 | $61K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 5,642 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,791 | $45K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,075 | $42K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,286 | $42K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 517 | $36K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,383 | $35K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 909 | $31K |
| 97162 | <1% | 261 | $27K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,286 | $24K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,190 | $24K |
| 80061 | Lipid panel | <1% | 2,345 | $24K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,679 | $21K |
| 73610 | <1% | 193 | $19K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,906 | $16K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,352 | $15K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 360 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,065 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 617 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 614 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,691 | $12K |
| 73630 | <1% | 94 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 258 | $11K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 5,153 | $11K |
| 99490 | Ccm add 20min | <1% | 1,804 | $10K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 407 | $10K |
| 85027 | <1% | 2,172 | $9K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 46 | $9K |
| 80306 | <1% | 902 | $9K | |
| 84484 | <1% | 2,334 | $9K | |
| 87400 | <1% | 826 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,106 | $8K |
| 87081 | <1% | 1,562 | $8K | |
| 83690 | <1% | 1,732 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,921 | $6K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 259 | $6K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,546 | $6K |
| 85610 | <1% | 2,538 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,837 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 61 | $5K |
| 84439 | <1% | 788 | $5K | |
| 97113 | <1% | 55 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 93 | $4K |
| 84703 | <1% | 793 | $4K | |
| 83735 | <1% | 1,166 | $4K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 793 | $4K |
| Q3014 | Telehealth originating site facility fee | <1% | 2,368 | $4K |
| 72100 | <1% | 41 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,000 | $3K |
| 87077 | <1% | 685 | $3K | |
| 86140 | <1% | 940 | $3K | |
| 81001 | <1% | 2,044 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 924 | $3K |
| 87186 | <1% | 582 | $3K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 680 | $3K |
| 73030 | <1% | 13 | $3K | |
| 97161 | <1% | 31 | $3K | |
| 97035 | <1% | 118 | $2K | |
| 83605 | <1% | 670 | $2K | |
| 81003 | <1% | 2,175 | $2K | |
| 73110 | <1% | 22 | $2K | |
| 87040 | <1% | 447 | $2K | |
| 83655 | <1% | 175 | $2K | |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | <1% | 29 | $2K |
| 86618 | <1% | 147 | $2K | |
| 80076 | <1% | 237 | $1K | |
| 85652 | <1% | 745 | $1K | |
| 72170 | <1% | 15 | $1K | |
| 81025 | <1% | 274 | $1K | |
| 82948 | <1% | 725 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 101 | $1K |
| 83880 | <1% | 104 | $1K | |
| 82728 | <1% | 132 | $1K | |
| 85730 | <1% | 429 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 46 | $1K |
| 86803 | <1% | 99 | $1K | |
| 85379 | <1% | 182 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 14 | $944.50 |
| 86703 | <1% | 63 | $896.03 | |
| 87430 | <1% | 96 | $888.11 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 37 | $812.70 |
| 96376 | <1% | 67 | $791.78 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 183 | $718.17 |
| 82607 | <1% | 79 | $701.70 | |
| 83540 | <1% | 132 | $604.57 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 93 | $557.58 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 150 | $537.41 |
| 99442 | <1% | 62 | $514.23 | |
| 87420 | <1% | 43 | $510.02 | |
| 84460 | <1% | 125 | $479.95 | |
| 84450 | <1% | 125 | $474.09 | |
| 87340 | <1% | 45 | $362.33 | |
| 82550 | <1% | 115 | $355.53 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 66 | $338.91 |
| 87070 | <1% | 65 | $329.41 | |
| 84145 | <1% | 69 | $307.70 | |
| 83550 | <1% | 49 | $302.35 | |
| 90686 | <1% | 122 | $284.14 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 54 | $269.75 |
| 82947 | <1% | 135 | $185.95 | |
| 84100 | <1% | 61 | $179.31 | |
| 86708 | <1% | 16 | $162.90 | |
| 80050 | General health panel | <1% | 14 | $127.27 |
| G0008 | Administration of influenza virus vaccine | <1% | 162 | $96.98 |
| 90653 | <1% | 21 | $24.73 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 213 | $3.28 |
| 90662 | <1% | 16 | $1.78 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 17 | $0.00 |
| A9270 | Non-covered item or service | 0% | 287 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHEINBLUM, RICHARD (CFO)
| Provider | Location | Paid |
|---|---|---|
| Monadnock Community Hospital | Peterborough, NH | $2.18M |
| Monadnock Community Hospital | Antrim, NH | $353K |
| Monadnock Healthy Teeth | Peterborough, NH | $31K |
| Monadnock Community Hospital | Peterborough, NH | $166.72 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.